Pfizer: No new formula against variants is needed

• Sileri: "No mask with 30 million vaccinated"

• From today almost all of Italy in 'yellow'.

  Vaccines, in Lombardy already more than 270 thousand people booked over 50

Share

May 10, 2021 "There are no indications" that a new Pfizer / BioNTech vaccine formula is needed against variants. The same company makes it known in a press release. "To date, there is no evidence that an adaptation of BioNTech's current Covid-19 vaccine is needed against the major emerging variants identified. Nonetheless, BioNTech has developed a comprehensive strategy to address these variants should the need arise in the future." , reads the note from the pharmaceutical company.

Total revenues of the Biontech group were estimated at € 2.048 billion for the three months ending March 31, 2021, compared to € 27.7 million for the three months ending March 31, 2020. The increase is mainly due to the rapid increased supply of COVID-19 vaccine around the world. BioNTech's commercial revenues include an estimated € 1,751.9 million which includes BioNTech's share of gross profit from sales of COVID-19 vaccines in Pfizer's territories.

BioNTech, the German pharmaceutical manufacturer of covid-19 vaccines, announced in a statement its intention to install a whey production facility in Singapore. Factory in Southeast Asia could produce hundreds of millions of doses per year Construction of the manufacturing facility and regional headquarters in Singapore will begin this year and could be operational by 2023.